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Objectives This study sought to provide a report to the public of data from the CathPCI Registry of the National Cardiovas-
cular Data Registry.
Background The CathPCI Registry collects data from approximately 85% of the cardiac catheterization laboratories in the
United States.
Methods Data were summarized for 6 consecutive calendar quarters beginning January 1, 2010, and ending June 30,
2011. This report includes 1,110,150 patients undergoing only diagnostic cardiac catheterization and 941,248
undergoing percutaneous coronary intervention (PCI).
Results Some notable findings include, for example, that on-site cardiac surgery was not available in 83% of facilities
performing fewer than 200 PCIs annually, with these facilities representing 32.6% of the facilities reporting, but
performing only 12.4% of the PCIs in this data sample. Patients 65 years of age or older represented 38.7% of
those undergoing PCI, with 12.3% being 80 years of age or older. Almost 80% of PCI patients were overweight
(body mass index 25 kg/m2), 80% had dyslipidemia, and 27.6% were current or recent smokers. Among pa-
tients undergoing elective PCI, 52% underwent a stress study before the procedure, with stress myocardial perfu-
sion being used most frequently. Calcium scores and coronary computed tomography angiography were used
very infrequently (3%) before diagnostic or PCI procedures. Radial artery access was used in 8.3% of diagnos-
tic and 6.9% of PCI procedures. Primary PCI was performed with a median door-to-balloon time of 64.5 min for
nontransfer patients and 121 min for transfer patients. In-hospital risk-adjusted mortality in ST-segment eleva-
tion myocardial infarction patients was 5.2% in this sample.
Conclusions Data from the CathPCI Registry provide a contemporary view of the current practice of invasive cardiology in the
United States. (J Am Coll Cardiol 2012;60:2017–31) © 2012 by the American College of Cardiology
Foundation
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Current State of U.S. Invasive Cardiology November 13, 2012:2017–31The National Cardiovascular
Data Registry (NCDR) of the
American College of Cardiology
Foundation (ACCF) was devel-
oped to assist healthcare provid-
ers and institutions in document-
ing their processes and outcomes
of care in the cardiac catheteriza-
tion laboratory. As a resource, the
NCDR is positioned to help
medical professionals and partic-
ipating hospitals identify and
close gaps in the quality of care;
reduce wasteful and inefficient
care variations; and implement
effective, continuous quality im-
provement processes. As we
move into the era of transparency
and public reporting, the value of
the NCDR is increasing, not
only for benchmarking out-
comes, but also as a potent repository of clinical data to
answer research questions.
History of the CathPCI Registry
A full description of the historical development of the
NCDR is presented elsewhere (1,2). Today, 1,488 facilities in
the United States are enrolled in the CathPCI Registry, which
captures an estimated 85% of the percutaneous coronary
interventions (PCI) performed in the United States (Fig. 1).
The Society for Cardiovascular Angiography and Interventions
collaborates with the ACCF on the registry effort.
Participation, Data Definitions, and Collection
Participation in the NCDR CathPCI Registry is voluntary.
Most participating facilities (68%) submit data on diagnos-
tic catheterization and PCI procedures, 29% submit data
only on PCI procedures, and 3% provide information only
on diagnostic procedures. Because interventional practices
are driven by technologies that change quickly, there have
been several registry modifications leading to the current
version 4.4 that began receiving data on April 1, 2011. This
version expanded data collection on pre-catheterization
imaging procedures, used a new bleeding definition, and
provided the first report of test metrics for assessment of the
appropriate use criteria for coronary revascularization. The
current version has 253 data fields, with definitions and
specifications available online (3). Data are collected up to
the time of hospital discharge, which is a potential limita-
tion (4).
Site Performance and Auditing Program
The NCDR Data Quality Program was developed to ensure
Abbreviations
and Acronyms
ACCF  American College
of Cardiology Foundation
BMS  bare-metal stent(s)
CABG  coronary artery
bypass graft
CAD  coronary artery
disease
DES  drug-eluting stent(s)
NCDR  National
Cardiovascular Data
Registry
PCI  percutaneous
coronary intervention
STEMI  ST-segment
elevation myocardial
infarction
STS  Society of Thoracic
Surgeonsthat data submitted are complete, consistent, and accurateand thus usable to improve the quality of clinical practice.
Participant submissions are reviewed for completeness and
are not accepted if data completeness criteria are unmet.
Each year, 25 sites are selected randomly for a comprehen-
sive on-site data audit. The structure of the Data Quality
Program and audit results recently were reported (5).
Several states conduct more extensive audits of data, because
they are used for statewide reporting programs.
NCDR Reports and Risk Adjustment Methods
Participants in the registry receive quarterly reports reflecting
their aggregate data and a rolling summary of the previous 4
quarters. Results from facilities with similar procedure volumes
and from the entire registry are provided for comparison with
a recent online tool developed to allow facilities to perform a
detailed analysis of their own data. An executive summary of
key metrics is provided in a box-and-whisker plot format
(Fig. 2). The NCDR provides an in-hospital risk-adjusted
mortality model that is endorsed by the National Quality
Forum (6,7). Bleeding and acute kidney injury risk models also
have been developed (8).
Figure 1 Cumulative Facilities and
Records in the CathPCI Registry
(Top) Facilities and (bottom) individual records in the registry. Dx Cath 
diagnostic cardiac catheterization; PCI  percutaneous coronary intervention.
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November 13, 2012:2017–31 Current State of U.S. Invasive CardiologyFigure 2 Box-and-Whisker Plot of Facility Performance
Example of a box-and-whisker plot used in the executive summary of the registry report.Figure 3 PCI Volume at Facilities With
and Without On-Site Cardiac Surgery
Abbreviation as in Figure 1.Figure 4 Percent of PCIs Performed at Low-Volume Facilities
Low-volume facilities are defined as performing fewer than 200 PCIs annually.
Q  quarter; other abbreviation as in Figure 1.
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These data provide a contemporary snapshot of diagnostic
cardiac catheterization and PCI as performed in the United
States, and thus provide an important perspective on many
aspects of invasive cardiac procedures, including their
Patient DemographicsTable 1 Patient Demographics
Patients
Undergoing PCI
(n  941,248)
Patients Undergoing
Only Diagnostic
Catheterization
(n  1,110,150)
Male/female (%) 67.4/32.6 55.9/44.1
Age
Median (yrs) 65 64
55 (%) 21.2 25.6
55 to 65 (%) 27.8 26.7
65 to 80 (%) 38.7 37.3
80 (%) 12.3 10.4
Race (%)
White 88.3 85.7
Black 8.1 11.4
Asian 2.1 1.7
American Indian/Alaskan 0.5 0.5
Hawaiian/Pacific Islander 0.2 0.2
Hispanic or Latino ethnicity 4.9 5.0
Insurance payers (%)*
Private 63.6 63.0
Medicare 51.2 49.2
Medicaid 9.3 10.9
Other 4.4 4.5
None 6.4 5.2
*Totals exceed 100% because many entries list more than 1 type of insurance payer.
PCI  percutaneous coronary intervention.
Figure 5 Sex and Age Distributions in the Registry
Age ranges are expressed in years. Cath  cardiac catheterization;
other abbreviation as in Figure 1.current use and outcomes (9). Summary reports from the
Implantable Cardioverter Defibrillator Registry have been
published (10), and it is the intent of the NCDR to publish
aggregate data from all its registries in the future.
The following sections provide an overview of invasive
cardiology as cataloged by the NCDR. The tabular data and
figures represent summary data for 6 consecutive calendar
quarters using version 4 beginning January 1, 2010, and
ending June 30, 2011. Data are presented in 2 groups
representing patients undergoing only diagnostic cardiac
catheterization (n  1,110,150) and patients undergoing
PCI (n  941,248) during their episode of care.
PCI volume per facility. Among the facilities included in
this report, 49% performed 400 or fewer PCI procedures
annually and 13% performed more than 1,000 PCI proce-
dures annually (Fig. 3). Three hundred thirty-nine facilities
(26%) performed 200 or fewer PCI procedures annually,
and these facilities accounted for approximately 4% of the
total PCI procedures (Fig. 4). PCI without on-site cardiac
surgery was performed at 32.6% of facilities, representing
12.4% of all PCI procedures performed. Among facilities
performing PCI without on-site surgery, 89% had a case
volume of fewer than 400 PCI procedures annually. Al-
though data showing a relationship between case volume
and outcomes are mixed and uncertain, the 2011 PCI
guidelines recommend that low-volume operators (fewer
than 75 cases annually) not perform PCI procedures at
Clinical CharacteristicsTable 2 Clinical Characteristics
Patients
Undergoing PCI
(n  941,248)
Patients Undergoing
Only Diagnostic
Catheterization
(n  1,110,150)
Body mass index
Median 29.1 29.6
Overweight (BMI 25 kg/m2) (%) 79.5 79.3
Obese (BMI 30 kg/m2) (%) 43.4 47.2
Thin (BMI 18.5 kg/m2) (%) 1.1 1.4
Prior (7 days) myocardial
infarction (%)
30.0 20.6
Prior heart failure (%) 11.8 NR
Prior PCI (%) 40.6 24.5
Prior PCI 1 yr (%) 33.9 NR
Prior CABG surgery (%) 18.8 13.6
Prior CABG surgery 5 yrs (%) 24.4 NR
Current/recent smoker (%) 27.6 NR
Hypertension (%) 82.0 NR
Dyslipidemia (%) 80.0 NR
Chronic lung disease (%) 15.2 NR
Diabetes mellitus (%) 36.2 33.6
Peripheral arterial disease (%) 12.5 NR
Cerebrovascular disease (%) 12.3 NR
GFR, mean  SD 75.6 30.6 NR
GFR 60 (%) 27.2 NR
Currently undergoing dialysis (%) 2.3 2.5
BMI  body mass index; CABG  coronary artery bypass graft; GFR  glomerular filtration rate;
NR  not reported; SD  standard deviation. Other abbreviation as in Table 1.low-volume facilities (fewer than 400 procedures annually)
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dures annually, unless geographically isolated, carefully con-
sider whether to continue to offer this service (11).
Registry demographics. Demographic data for patients
undergoing only diagnostic procedures and those undergo-
ing PCI are shown in Table 1. Approximately two-thirds of
those undergoing PCI were male, whereas 56% of those
undergoing diagnostic study were male (Fig. 5). Median age
and the age distribution were similar for the 2 groups, with
approximately half of the patients being 65 years of age or
older and approximately 10% of the patients being 80 years
of age or older (Fig. 5). Coronary intervention was per-
formed during the same laboratory session as the diagnostic
catheterization (so called ad hoc PCI) in 85.7% of the
records.
Clinical characteristics and presentation. Approximately
80% of the patients were overweight (body mass index 25
kg/m2), approximately 45% were obese, and approximately
1% were considered thin (body mass index 18.5 kg/m2)
(Table 2, Fig. 6). The occurrence of other clinical charac-
teristics and risk factors also is shown. Among diabetic
patients undergoing PCI, 36% were treated with insulin,
52% were treated with oral agents, 6% were treated with diet
alone, and 5% were receiving no treatment.
Among patients undergoing PCI, approximately 70%
had some type of acute coronary syndrome at presentation
(unstable angina, non–ST-segment elevation myocardial
infarction, ST-segment elevation myocardial infarction
[STEMI]), 17.6% had stable angina, and 12% had either
atypical symptoms or no angina (Table 3, Fig. 7). In
comparison, of those undergoing only diagnostic study,
43.5% had an acute coronary syndrome at presentation—
mostly unstable angina, 21.4% had stable angina, and 35.2%
had either atypical or no symptoms. Heart failure within the
previous 2 weeks, cardiogenic shock within the previous
24 h, and cardiac arrest were uncommon at the time of
presentation in both groups. Pre-operative diagnostic cath-
Figure 6 Clinical Characteristics of Patients Undergoing PCI
BMI  body mass index in kilograms per square meter; other abbreviation as in Feterization before noncardiac surgery was uncommon
e
a(4.9%), as was pre-operative PCI (2.0%). Medication use,
especially in patients undergoing PCI, has been examined
recently within the NCDR database (12). Nearly 70% of
patients undergoing PCI were prescribed antianginal med-
ications within 2 weeks of their procedure; 44% had 1 drug
prescribed, whereas 24% had 2 or more drugs prescribed.
Clinical PresentationTable 3 Clinical Presentation
Patients
Undergoing PCI
(n  941,248)
Patients
Undergoing Only
Diagnostic
Catheterization
(n  1,110,150)
CAD presentation (%)
No symptoms and no angina 9.0 17.6
Symptoms unlikely to be ischemic 3.0 17.6
Stable angina 17.6 21.4
Unstable angina 36.7 33.0
NSTEMI 17.9 8.8
STEMI 15.8 1.7
Heart failure within the previous 2 weeks (%) 9.6 13.6
Cardiogenic shock within the preceding
24 h (%)
1.9 0.7
Cardiac arrest within the preceding 24 h (%) 1.9 0.7
Pre-operative evaluation/treatment
before noncardiac surgery (%)
2.0 4.9
Medications
Antianginals in the preceding 2 weeks 68.0 60.3
Patients with ACS (%) 67.3 66.7
Patients without ACS (%) 69.7 55.4
One antianginal prescribed (%) 44.1 NR
2 antianginals prescribed (%) 23.9 NR
Among patients with some antianginal
Beta-blockers (%) 87.0 NR
Calcium-channel blockers (%) 22.5 NR
Long-acting nitrates (%) 26.1 NR
Ranolazine (%) 2.4 NR
Other antianginal agent (%) 4.2 NR
ACS  acute coronary syndrome; CAD  coronary artery disease; NSTEMI  non–ST-segment
.igure 1levation myocardial infarction; STEMI  ST-segment elevation myocardial infarction; other
bbreviation as in Tables 1 and 2.
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prescribed, beta-blockers were used most frequently (87%),
followed by long-acting nitrates (26.1%) and calcium-
channel blockers (22.5%).
Use of stress testing, calcium scores, and coronary com-
puted tomography imaging. Among patients undergoing
diagnostic catheterization, 45.5% underwent some type of
stress test before their procedure, but it is important to note
that this includes patients undergoing study for all indica-
tions, not just coronary artery disease (CAD) (Table 4).
Among patients undergoing PCI, 33.6% had undergone
some type of stress study before PCI, but not all patients
undergoing PCI would be appropriate candidates for a stress
study. If patients who would likely not undergo stress
testing are excluded (immediate PCI for STEMI, PCI for
STEMI in unstable patients more than 12 h from symptom
onset, rescue PCI for failed fibrinolytics, and PCI for
high-risk non–ST-segment elevation myocardial infarction
or unstable angina), 52.0% of patients underwent some type
of stress test before PCI. As a PCI quality metric, the
proportion of elective PCIs with either an abnormal stress
study suggesting ischemia or a fractional flow reserve mea-
surement 0.8 or less before PCI was assessed. The 50th
percentile for this metric among all facilities was 58.7%;
facilities in the top 10% for this metric obtained such testing
in 76.9% of elective PCIs.
The dominant form of stress testing used was a myocar-
dial perfusion study (Fig. 8). Across all types of stress studies
Figure 7 Clinical Presentation of Patients in the CathPCI Regis
No Sx  no symptoms; NSTEMI  non–ST-segment elevation myocardial infarction
other abbreviations as in Figures 1 and 5.in patients undergoing PCI, 9% to 12% demonstratednegative results, 3% to 6% demonstrated indeterminate
results, and 81% to 88% demonstrated abnormal results. An
assessment of ischemic risk from the stress study was
provided in approximately 60% of the patients and indicated
intermediate or high risk in 79% to 87% of PCI patients and
in 66% to 76% of those undergoing diagnostic cardiac
catheterization. Less than 1% of patients in the database
underwent stress testing using magnetic resonance imaging.
Overall, coronary calcium scores and coronary computed
tomography angiography were performed in few patients
before the procedure.
Procedural characteristics. For both diagnostic procedures
and PCI, femoral access remains the most frequently used
technique (Table 5). Mean and median fluoroscopy times
for the entire cohort undergoing diagnostic catheterization
are shown. These times are affected by the need to image
bypass grafts if present and other diagnostic imaging such as
left ventriculography. Because most PCI procedures were
performed ad hoc, fluoroscopy time further depended on the
number of vessels or lesions treated. Therefore, times were
stratified further for single-vessel or single-lesion procedures
versus multivessel procedures. As total radiation exposure
receives greater attention, the values shown for fluoroscopy
times are useful benchmarks for facilities to identify opera-
tors who may use excessive radiation consistently for pro-
cedures. Mean and median amounts of radiographic con-
trast, stratified in a similar manner, also are provided in
MI  ST-segment elevation myocardial infarction;try
; STETable 5.
d 3.
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to obtain hemostasis for both diagnostic studies and PCI
(Fig. 9). Sealant-type devices are the next most frequently
used, whereas staple closure devices represented less than
0.1% of the devices used.
Medications. Anticoagulant and antiplatelet use is shown
in Figure 10. Overall, aspirin was given within the 24 h
before and during PCI in 87.8% of patients and was
contraindicated in 0.7% of patients. By hospital discharge,
nearly all patients without a contraindication were receiving
aspirin; the 50th percentile of aspirin administration at
discharge was 97.9% among all facilities, and in the 90th
percentile (top 10% of performers), the aspirin administra-
tion rate was 99.7%. Clopidogrel was the most frequently
used thienopyridine (76%), with prasugrel used in 11.2% of
patients and ticlopidine used in only 0.25% of patients.
Ticagrelor was not available commercially during this survey
period. By hospital discharge, nearly all patients were
receiving a thienopyridine; the 50th percentile of thien-
opyridine use among all facilities was 98.9% and the 90th
percentile was 100%. Fondaparinux was used rarely (1.1%)
in patients before or during PCI, with unfractionated
heparin or bivalirudin used approximately equally (51% and
56%, respectively). Glycoprotein IIb/IIIa inhibitors were
used overall in 28.7% of PCIs and slightly more frequently
Use of Stress Testing and Calcium Scores and CTable 4 Use of Stress Testing and Calcium
Entire cohort
Stress or imaging study performed (%)
If performed, abnormal (positive) study (%)
Low-/intermediate-/high-risk test (%)
Type of stress test (when performed)
Standard stress test (%)
Results: negative/indeterminate/abnormal (%)*
Ischemic risk: low/intermediate/high (%)†
Stress echocardiogram (%)
Results: negative/indeterminate/abnormal (%)*
Ischemic risk: low/intermediate/high (%)†
Stress myocardial perfusion imaging (%)
Results: negative/indeterminate/abnormal (%)*
Ischemic risk: low/intermediate/high (%)†
Coronary calcium score performed (%) (among stress
or imaging population)
 100/101 to 400/400 (%)
Coronary CT angiogram performed (%) (among stress
or imaging population)
No disease (%)
1/2/3-vessel disease (%)
Indeterminate (%)
Unavailable
*Results missing: diagnostic catheterization: 0.38%, PCI: 0.19% for
echocardiogram; diagnostic catheterization: 0.14%, PCI: 0.09% for
PCI: 0.39% for calcium score; diagnostic catheterization: 0.14%, P
available.
CT  computed tomography. Other abbreviations as in Tables 1 anamong patients with an acute coronary syndrome (34.0%).By hospital discharge, nearly all patients without a contra-
indication were receiving a statin medication; the 50th
percentile among facilities for the administration of a statin
at discharge was 90.5% and the 90th percentile was 96.5%.
Diagnostic procedure findings and recommendations.
Considering patients undergoing only diagnostic proce-
dures, 49.8% had either no CAD or nonobstructive CAD,
whereas only 0.2% in the PCI cohort were classified as
having all stenoses less than 50% in severity (Table 6). This
seems to suggest that many diagnostic procedures were per-
formed on patients without significant CAD. However, diag-
nostic studies are performed for reasons besides CAD. A more
informative quality metric was developed for elective diagnostic
procedures excluding patients: 1) with prior coronary artery
bypass graft (CABG); 2) undergoing cardiac transplantation
evaluation; 3) undergoing pre-operative evaluation for noncar-
diac surgery; and 4) those with a treatment recommendation
other than PCI or CABG. An example of the latter would be
an older patient with isolated valvular disease in whom coro-
nary angiography is performed before valve surgery. In this
restricted cohort, procedures with the finding of all coronary
stenosis of less than 50% occurred at a median of 44.5% among
facilities; at the 90th percentile, the value for all coronary
stenosis of less than 50% was 32.6%. Furthermore, because a
coronary stenosis of less than 50% can be associated with
ary CT Angiographys and Coronary CT Angiography
ents Undergoing
PCI
n  941,248)
Patients Undergoing
Only Diagnostic Catheterization
(n  1,110,150)
33.6 45.5
81.8 77.7
9.7/49.8/30.4 32.0/49.3/18.7
8.3 8.8
2.2/6.0/81.8 14.9/8.5/76.6
2.5/48.4/39.1 23.8/53.0/23.2
10.5 10.9
2.3/6.4/81.3 16.7/9.5/73.8
5.4/49.5/35.0 24.1/53.7/22.2
81.9 81.1
9.4/2.9/87.7 12.5/4.9/82.6
0.8/50.1/29.1 33.5/48.6/17.8
1.6 1.2
3.8/24.2/60.9 20.6/23.9/53.8
2.7 1.7
2.5 8.6
7.2/25.3/20.9 32.3/19.4/17.8
3.9 7.8
10.1 14.0
rd stress test; diagnostic catheterization: 0.4%, PCI: 0.2% for stress
myocardial perfusion imaging; diagnostic catheterization: 0.56%,
% for coronary CT angiogram. †Among those with risk assessmentoronScore
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of less than 50% stenosis in a large number of patients does not
automatically indicate an overuse of diagnostic angiography
(13). However, as previously reported, there is significant
interhospital variation in the rate of finding obstructive CAD
among patients undergoing elective, diagnostic coronary an-
giography (14). Left main disease (50%) was found in 8.2%
of patients undergoing diagnostic study and in 6.4% of patient
undergoing PCI, usually in conjunction with additional CAD.
Among patients undergoing only diagnostic study, the
treatment recommendations were medical therapy in 69.2%,
CABG in 13.0%, no subsequent therapy in 9.2%, and other
cardiac therapy without CABG or PCI in 6.3%. In 2.1%,
PCI without planned CABG was recommended, but was
performed as a separate procedure. The indications for PCI
are also shown in Table 6 and Figure 11.
PCI characteristics. Characteristics of the entire cohort of
patients undergoing PCI are shown in Table 7 and Figure 12.
In 6.0% of the total lesions, PCI of a bypass graft was
performed, mostly in vein grafts, with 58.4% occurring in
the body of the vein graft. Although PCI of arterial grafts
Figure 8 Use of Stress Testing in the Registry
(A) Patients undergoing only Dx Cath and (B) those undergoing PCI. The blue
bars indicate the frequency of use for the particular test, the red bars indicate
the percent of those tests interpreted as having abnormal results, and when
available, the green bars indicate the percent of tests that were intermediate
or high-risk tests. ECG  electrocardiogram; Echo  echocardiography; MPI 
myocardial perfusion image; other abbreviations as in Figures 1 and 5.was uncommon, when performed, it was most frequently at tthe distal anastomosis or in the graft body. Data on devices
used were collected, and their use on a per-procedure basis
was estimated. All of the adjunctive devices were used
infrequently. At least 1 drug-eluting stent (DES) was used
in 69.8% of PCI patients, a bare-metal stent (BMS) with no
DES was used in 21.5% of PCI patients, and balloon
angioplasty without stent use was used in 8.7% of patients.
On average, 1.4 stents were placed per procedure per-
formed. When DES were used, 61.6% of the patients
received just 1 DES, 26.2% had 2 DES used, 8.6% had 3
DES used, and 3.6% had 4 or more DES used. When BMS
were used, 70.0% of the patients received just 1 BMS,
21.9% had 2 BMS used, 6.0% had 3 BMS used, and 3.6%
had 4 or more BMS used. The longest lesion length treated
during PCI was more than 25 mm in 23% of patients, 10
mm or more but less than 15 mm in 24.5%, and less than 10
mm in 7.7% of patients. Bifurcation lesions were treated in
13% of patients.
Approximately 13% of all stenoses treated by PCI were
graded between 40% and 70% in severity. In this subgroup,
25% were evaluated further by either intravascular ultra-
sound (18%) or fractional flow reserve measurements (7%).
In patients with stenoses graded between 40% and 70% in
severity treated by PCI, only 8.3% had either no angina or
normal stress test results, and approximately 23% of these
stenoses were further evaluated by intravascular ultrasound
or fractional flow reserve measurements.
Cardiogenic shock was present in the preceding 24 h in
1.9% of patients undergoing PCI during admission (Table 3)
and developed during or after PCI in 0.47% of patients
(Table 8). Some type of mechanical support device was used
in 2.9% of all PCIs performed. This was dominated by the
intra-aortic balloon pump that was used alone in 84.4% of
the cases with mechanical support or with another support
device in 4.7%. However, the timing of support device
insertion was different between intra-aortic balloon pumps
and other support devices. When intra-aortic balloon
pumps were used, they were in place before the procedure in
8.1%, were inserted during the procedure and before PCI in
29.3%, and inserted after the start of the PCI in 62.6%. By
contrast, when other forms of mechanical support were
used, they were in place at the start of the procedure in
36.3%, were inserted during the procedure and before PCI in
46.2%, and were inserted after the start of the PCI in 17.4%.
Complications during diagnostic cardiac catheterization
and in PCI patients without STEMI. Any adverse event
occurred in 4.53% of patients undergoing PCI and in 1.35%
of patients undergoing diagnostic cardiac catheterization
(Table 8). Any bleeding within 72 h occurred in 1.40% of
PCI patients without STEMI and in 0.49% of patients
undergoing diagnostic cardiac catheterization without
STEMI. Figure 13 shows the type of bleeding event that
ccurred in patients undergoing diagnostic catheterization
nd PCI with or without STEMI.
TEMI quality metrics and complications. Table 9 shows
he quality metrics and complications in STEMI patients.
Values are %, mean  SD, or median (25th, 75th).
Abbreviations as in Tables 1 and 2.
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PCI for nontransfer STEMI patients (door-to-balloon
time) was 64.5 min—a marked reduction in door-to-
balloon times over a few years that reflect the success of
focused process improvement initiatives (15). Nonsystem
delays were identified in STEMI patients with a door-to-
s Undergoing
PCI
941,248)
Patients Undergoing
Only Diagnostic Catheterization
(n  1,110,150)
7/0.4/6.9 91.2/0.4/8.3
.5 11.5 4.9 5.71
7.2, 18.1) 3.1 (2.0, 5.8)
6.9, 16.8) 2.8 (1.8, 5.0)
.0 9.9
6.2, 14.5)
.7 12.2
10.0, 22.0)
10.0, 23.3) 6.7 (4.2, 10.7)
.8 12.2
9.1, 21.0)
.7 14.5
13.0, 28.4)
.4 90.1 103.2 48.5
137.0, 245.0) 96.0 (73.0, 125.0)
135.0, 240.0) 90.0 (70.0, 120.0)
.9 79.2
125.0, 220.0)
.9 97.9
164.0, 280.0)
149.0, 261.0) 128.0 (96, 170.0)
.0 91.1
137.0, 250.0)
.8 106.8
170.0, 300.0)
Figure 10 Medications Used During
Percutaneous Coronary Intervention
GPIIb/IIIa  glycoprotein IIb/IIIa inhibitor; LMWH  low-molecular-weight heparin;
UFH  unfractionated heparin.Procedure CharacteristicsTable 5 Procedure Characteristics
Patient
(n 
Vascular access
Femoral/brachial/radial 92.
Fluoroscopy time (min)
Mean (all studies) 14
Median (all studies) 11.4 (
Patients without CABG 10.6 (
PCI of 1 vessel/lesion 12
PCI of 1 vessel/lesion 9.3 (
PCI 1 vessel/lesion 17
PCI 1 vessel/lesion 14.7 (
Patients with CABG 15.2 (
PCI of 1 vessel/lesion 16
PCI of 1 vessel/lesion 13.8 (
PCI 1 vessel/lesion 22
PCI 1 vessel/lesion 19.4 (
Contrast volume (ml)
Mean (all studies) 197
Median (all studies) 182.0 (
Patients without CABG, median (25th, 75th) 180.0 (
PCI of 1 vessel/lesion 179
PCI of 1 vessel/lesion 170.0 (
PCI 1 vessel/lesion 230
PCI 1 vessel/lesion 220.0 (
Patients with CABG 200.0 (
PCI of 1 vessel/lesion 199
PCI of 1 vessel/lesion 190.0 (
PCI 1 vessel/lesion 243
PCI 1 vessel/lesion 230.0 (Figure 9 Hemostasis Technique Used in Procedures
Abbreviations as in Figures 1 and 5.
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nonsystem delay included difficult vascular access (7.4%),
cardiac arrest or need for intubation before PCI (36.2%),
delays in providing consent for PCI (4.4%), difficulty
Diagnostic Procedure Findings and RecommendTable 6 Diagnostic Procedure Findings and
Coronary dominance (%)
Left/right/mixed
Extent of CAD (%)
Nonobstructive CAD (all stenosis 50%)
1-vessel disease
2-vessel disease
3-vessel disease
Treatment recommendation after diagnostic study (%)
None
Medical therapy and/or counseling
CABG (including hybrid PCI/CABG procedures)
PCI without planned CABG
Other cardiac therapy without CABG or PCI
Missing or no diagnostic study associated with PCI
Indication for PCI (%)
Primary PCI for STEMI
PCI for STEMI (unstable 12 h from Sx onset)
PCI for STEMI (stable 12 h from Sx onset)
PCI for STEMI (stable after full-dose fibrinolytics)
Rescue PCI (after failed full-dose fibrinolytics)
PCI for high-risk NSTEMI or unstable angina
Staged PCI
Other (including stable angina)
Sx  symptoms; other abbreviations as in Tables 1, 2, 3, and 4.
Figure 11 Indication for PCI
Abbreviations as in Figures 1 and 7.crossing the culprit lesion during PCI (17.4%), and other
reasons in (34.6%).
The 50th percentile for hospital risk-adjusted mortality
rate among STEMI patients was 5.2%, and facilities in the
smmendations
ts Undergoing
PCI
941,248)
Patients Undergoing
Only Diagnostic Catheterization
(n  1,110,150)
/79.4/7.7 10.9/78.1/7.9
0.2 49.8
38.1 15.9
32.6 12.9
39.1 21.1
0.3 9.2
1.1 69.2
0.8 13.0
83.4 2.1
0.1 6.3
14.4 0.1
13.9
0.9
0.6
0.5
0.5
45.0
6.4
32.3ationReco
Patien
(n 
9.2
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mortality rate of 3.3%. The top 10th percentile for risk-
adjusted STEMI mortality is not reported because it likely
was skewed by the number of low-volume facilities report-
ing no STEMI mortalities. Among STEMI patients un-
dergoing PCI, any adverse event occurred in 12.4%, with
PCI CharacteristicsTable 7 PCI Characteristics
No. of vessels treated during PCI (%)
1 vessel 86.2
2 vessels 12.8
3 vessels 0.7
Multivessel PCI 13.5
Lesion location (1,275,208 lesions treated) (%)
Left main 1.8
Left anterior descending 37.2
Circumflex 24.1
Ramus 1.6
Right coronary artery 34.9
Bypass graft lesions 6.0
Vein (% of total PCIs) 5.5
Aortic anastomosis 22.1
Body of vein graft 58.4
Distal anastomosis 19.0
Internal mammary or other arterial graft (% of total PCIs) 0.3
Aortic anastomosis 18.3
Body of arterial graft 38.6
Distal anastomosis 41.3
Intracoronary devices used (2,992,180 total devices used) (%)
Atherectomy 1.2
Laser 0.3
Extraction catheter 3.2
Cutting balloon 6.4
Embolic protection device (based only on SVGs treated) 8.0
Thrombectomy device 5.7
941,248 PCI procedures. Values are %.
SVG  saphenous vein graft; other abbreviation as in Table 1.
Figure 12 Vessels Treated During PCI
(Left) Number of vessels treated during PCI and (right) the specific vessel treated
SVG  saphenous vein graft; other abbreviation as in Figure 1.specific complications shown in Table 9 and bleeding
complications in Figure 13.
PCI success and mortality by patient status. Procedure
success typically is defined as angiographic success without
associated in-hospital major clinical complications (e.g.,
death, myocardial infarction, stroke, emergency CABG)
(11). Because of the known variability in the visual assess-
ment of stenosis severity and the high likelihood of a good
visual result after stent deployment, angiographic success no
longer is reported from the CathPCI Registry. However, to
provide some perspective for this report, PCI success was
defined as completion of the procedure without death,
CABG related to PCI failure, PCI failure without
clinical deterioration, stroke, pericardial tamponade, or
need for dialysis and is shown in Figure 14. Myocardial
infarction was not included in this definition because
cardiac enzymes were not collected consistently in pa-
tients after PCI.
For diagnostic procedures, 65.5% were classified as
elective, 31.4% were classified as urgent, 3.0% were
classified as emergent, and 0.1% were classified as salvage.
For PCI procedures, 44.8% were classified as elective,
37.5% were classified as urgent, 17.3% were classified as
emergent, and 0.3% were classified as salvage. Unadjusted
mortality for PCI patients in these categories is shown in
Figure 15.
Future Directions
The value of the CathPCI Registry will be demonstrated as
it is used to understand further the practice of invasive
cardiology and to drive a higher level of quality into
individual physician practice. The ACCF and its registry
partners are committed to expanding the NCDR to its full
potential as the delivery of health care continues to evolve.
 left anterior descending; RCA  right coronary artery;. LAD
tions a
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Registry has been the substrate for more than 70 publica-
tions in the peer-reviewed medical literature and for more
than 200 abstracts presented at national meetings. These
and additional publications continue to provide key insights
into the important clinical issues in the rapidly changing
field of invasive cardiology.
Procedure-Related Complications in Patients WTable 8 Procedure-Related Complications in
Complications (%)
Any adverse event
Cardiogenic shock
Heart failure
Pericardial tamponade
CVA/stroke
% of total strokes that were hemorrhagic
New requirement for dialysis
In-hospital mortality
Non–risk-adjusted
Non–risk-adjusted excluding CABG patients
CABG performed during admission
CABG status
Salvage/emergency
Urgent/elective
CABG indication
PCI failure without clinical deterioration
PCI complication
Bleeding complications (%)
Any bleeding event within 72 h of procedure
Any other vascular complication requiring treatment
RBC/whole-blood transfusion
CVA  cerebrovascular accident; RBC  red blood cell; other abbrevia
Figure 13 Type of Bleeding Complications
GI  gastrointestinal; GU  genitourinary; STEMI  ST-segment elevation myocardNCDR data for maintenance of certification. Physicians
who have a time-limited board certification from the Amer-
ican Board of Internal Medicine must complete a Main-
tenance of Certification process to renew their certifica-
tion. CathPCI Registry data can be used to complete
American Board of Internal Medicine’s Self-Directed
Practice Improvement Module and meet the American
t STEMIents Without STEMI
PCI Patients
ithout STEMI
n  787,980)
Diagnostic Catheterization Only
Patients Without STEMI
(n  1,091,557)
4.53 1.35
0.47 0.24
0.59 0.38
0.07 0.03
0.17 0.17
15.6 9.16
0.19 0.14
0.65 0.72
0.62 0.60
0.81 7.47
0.01/0.17 0.01/0.27
0.47/0.16 5.27/1.92
0.26
0.14
1.40 0.49
0.44 0.15
2.07 N/R
s in Tables 1 and 2.
arction; other abbreviations as in Figures 1 and 7.ithouPati
W
(ial inf
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Performance requirement (16). The goal is to use actual
data from an individual’s practice setting to drive quality
improvement efforts. Moving forward, there are many
additional areas where the organizations share common
goals for collaboration, including efforts to enhance life-
long learning.
Public reporting. Public reporting of outcomes is increas-
ing in an attempt to encourage both physicians and hospitals
to become engaged in quality efforts, to improve areas where
problems exist, and to provide patients with information
about comparative performance. Public reporting of cardiac
STEMI Quality Metrics and PCI ComplicationsTable 9 STEMI Quality Metrics and PCI Complications
All Hospitals
50th
Percentile
90th
Percentile
Process metrics
Median time to PCI for STEMI patients (min)
excluding transfer-in patients and
those with acceptable reason for delay
64.5 52.0
Proportion receiving PCI in 90 min (%)
excluding transfer-in patients and
those with acceptable reason for delay
89.9% 97.7%
Median time from ED arrival at transferring
facility to ED arrival at STEMI receiving
facility (min)
88.0 58.0
Median time from ED arrival at transferring
facility to immediate PCI at STEMI
receiving facility (min)
121.0 85.0
Quality metrics
In-hospital risk-adjusted mortality: STEMI
patients (%)
5.2 3.3*
Utilization metrics
Median post-procedure LOS for PCI patients
with STEMI
3.0 2.0
Incidence (%)
PCI complications during admission: STEMI
patients (n  153,268)
Any adverse event 12.4
Cardiogenic shock 3.87
Heart failure 3.46
Pericardial tamponade 0.15
CVA/stroke 0.56
% of total strokes that are hemorrhagic 19.7
New requirement for dialysis 0.63
CABG performed during admission
CABG status
Salvage/emergency 0.05/0.87
Urgent/elective 2.08/0.43
CABG indication
PCI failure without clinical deterioration 0.58
PCI complication 0.22
Bleeding complications
Any bleeding event within 72 h of procedure 3.85
Any other vascular complication requiring
treatment
0.62
RBC/whole-blood transfusion 5.61*This represents the top 25th percentile rather than the top 10th percentile.
ED emergency department; LOS length of stay; other abbreviations as in Tables 1, 2, 3, and 8.surgical outcomes is not new and exists in several states, and
the Society of Thoracic Surgeons (STS) recently instituted
a voluntary public reporting effort with Consumer’s Union
(17,18). For such reporting, there is an important distinc-
tion between administrative (claims) data and clinical data
sources. Disparities in the results between these 2 datasets
have been demonstrated, with report cards using only
administrative data often being different when compared
with those derived from audited and validated clinical data
(19). Concern exists that such programs may lead to
unintended consequences that could offset their benefits
(20). The NCDR is developing a plan for voluntary public
reporting of selected NCDR data. Public reporting efforts of
the STS have been received favorably, and the NCDR will
follow the principles set forth by the ACCF (21,22).
NCDR collaborative research. The ASCERT (American
College of Cardiology Foundation–The Society of Thoracic
Surgeons Collaboration on the Comparative Effectiveness
of Revascularization sTrategies) study is a unique collabo-
ration between the ACCF and the STS (23). This study
compared catheter-based and surgery-based revasculariza-
tion procedures for stable CAD using existing databases
from the ACCF and STS, as well as the Centers for
Medicare and Medicare Services 100% denominator file data.
Other efforts to merge NCDR data with longitudinal admin-
istrative datasets provides an efficient and low-cost method to
perform longitudinal outcome assessments (24,25).
International expansion. Beginning in February 2011,
Sheikh Khalifa Medical City in Abu Dhabi, United Arab
Emirates, began data collection for the ACTION Registry-
GWTG and CathPCI Registry. Discussions are underway
to include NCDR participation for all hospitals in this
system and with several other international facilities. Fur-
ther international expansion of the NCDR provides several
unique opportunities for comparisons among regions and
Figure 14 PCI Success
See text for the definition of success. Abbreviations as in Figures 1 and 7.different systems of care.
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